

## Effect of an Anti Inflammatory on Cognitive Deficits in Diabetic Rats

Eric Gueumekane Bila Lamou<sup>1\*</sup>, Ghislain Loubano-Voumbi<sup>2</sup>, Mor Diaw<sup>1</sup>, Salimata Diagne Houndjo<sup>1</sup>, Valentin Ouedraogo<sup>1</sup>, Abdoul Khadir Sow<sup>1</sup>, Abdoulaye Ba<sup>1</sup> and Abdoulaye Samb<sup>1</sup>

<sup>1</sup>UCAD, Senegal

<sup>2</sup>Reference Hospital of Dolisie, Congo

Diabetes is a multifactorial pathology implicating a genetic predisposition and metabolic disorders acquired, which leads to the progressive deterioration of the action of insulin secretion. The international epidemiologic data's concerning the prevalence of diabetes show important disparities between the different countries studied. Whereas, it testifies uniformly from a considerable increase of its frequency in the developing countries. The previsions at the world level estimates that the number of diabetic subjects will leave from 171 million in 2000 to 366 million in 2030. This prevalence is generally underestimated because of hyperglycemia can evaluate in a silent way, during numerous years before the diagnosis is being done. The cost of management diabetes posing an important and increase problem in Public health, long term consequences linked to microangiopathy and macroangiopathy of diabetes constitute invalid pathologies and implicates a heavy management of patients. A couple of epidemiologic arguments, clinical and experimental accumulated in the course of the last 10 years, pleads in favor of a disfavoured effect of the inflammation in a low sound of adipose tissue in the up come of diabetes as well as the neuroinflammation responsible for numerous cognitive disorders notably anxiety and memory disorders. To our knowledge, there exist less data of the literature concerning the action of anti-inflammatory on cognitive disorders. In this context, the objective of our study was to evaluate the effect of acetylsalicylic acid on cognitive deficits in diabetic rat, that which could be one of the interesting therapeutic to explore.

### Biography:

Eric Gueumekane Bila Lamou is from Cameroon, he has completed his specialization in Clinical Neurology in 2016 at Cheikh Anta Diop University of Dakar/Senegal and he have been awarded of IFCN Africa Scholarship for the year 2017 for Young Clinical Neurophysiologist. Actually he is doing PhD program in Neurophysiology at the same University. He has published some papers in reputed Journals.